MEDICINAL COMPOSITION FOR INHALATION

A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful...

Full description

Saved in:
Bibliographic Details
Main Authors TANI, KOUSUKE, YAMAMOTO, SHIGEKI, NAGASE, TOSHIHIKO, SHIROYA, TSUTOMU, MARUYAMA, TORU, KADODE, MICHIAKI
Format Patent
LanguageEnglish
French
Japanese
Published 27.04.2006
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and/or a remedy for respiratory diseases (for example, asthma, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, cystic fibrosis, pulmonary hypertension or the like) without causing any systemic effect such as lowering blood pressure. Thus, a safe and useful remedy for respiratory diseases is provided. La présente invention a pour objet une préparation thérapeutique pour inhalation, qui contient une prodrogue de type relargage en continu correspondant à un agoniste de l'EP2. Ladite préparation induit localement des effets prolongés de type bronchodilatation et anti-inflammation. En particulier, ladite préparation peut être employée sans risque en tant que médicament prophylactique et/ou thérapeutique pour le traitement de maladies respiratoires (par exemple l'asthme, les blessures pulmonaires, la fibrose pulmonaire, les emphysèmes pulmonaires, la bronchite, la bronchopneumopathie chronique obstructive, le syndrome de détresse respiratoire de l'adulte, la fibrose kystique, l'hypertension pulmonaire et des maladies similaires) sans causer d'effet systémique tel que la diminution de la pression artérielle. Ainsi, il est possible de mettre au point un médicament efficace et sans risque pour traiter les maladies respiratoires.
Bibliography:Application Number: WO2005JP19376